Street Calls of the Week
WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a $175 million market cap biotech company whose stock has surged 87% over the past year, announced Thursday that its pipeline product TVGN 930, targeting non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV), has a projected cumulative 5-year top-line revenue of approximately $3.5 billion.
The company estimates the risk-adjusted Net Present Value (rNPV) for TVGN 930 exceeds $250 million in the U.S. market alone. The treatment targets five rare disease eligible indications with a potential U.S. market of up to 40,000 patients. According to InvestingPro data, while currently operating at a loss with -$31 million EBITDA, analysts have set an ambitious $10 price target for the stock, suggesting significant upside potential from its current $0.88 trading price.
Tevogen’s Chief Commercial Officer Sadiq Khan noted the significant therapeutic gap in EBV treatment. "As of July of this year, there are no approved vaccines for EBV. This together with the absence of effective therapeutics poses a significant challenge for oncologists treating these malignancies," Khan stated.
The company indicated that the treatment of multiple sclerosis through tighter EBV control could represent an additional opportunity for TVGN 930.
Tevogen highlighted its "unique, faster, and cost-efficient drug development model" as a factor in the forecast. The company referenced its first clinical stage product, TVGN 489, developed for treating SARS-CoV-2 in immunocompromised patients, as evidence of its ability to reach development milestones rapidly.
The company plans to share additional valuation updates on its product pipeline and other assets in the future, according to the press release statement. InvestingPro analysis reveals several additional key metrics and insights about Tevogen’s financial health and market position. Subscribers can access 5 more exclusive ProTips and detailed financial metrics to make more informed investment decisions.
In other recent news, Tevogen Bio Holdings Inc. reported a significant increase in institutional ownership, with a 60% rise in the first quarter of 2025 compared to the previous quarter. This growth was largely driven by Vanguard and BlackRock, who together increased their holdings by 151%. Additionally, Tevogen announced it expects to receive $1 million in grant funding from KRHP LLC to further its Tevogen.AI platform, part of a larger $10 million non-dilutive funding agreement. The company also highlighted that its executive officers and board members collectively own over 74% of the company’s stock, ensuring substantial control over its strategic direction.
Further developments include the Board of Directors’ decision to grant 8 million restricted shares to CEO Dr. Ryan Saadi, bringing the total outstanding shares to 193,693,433. The vesting of these shares is set to begin seven years from the grant date. In addition, Tevogen emphasized the need for SARS-CoV-2 treatments for immunocompromised individuals, spotlighting its investigational therapy, TVGN 489. These updates reflect Tevogen’s ongoing strategic initiatives and developments in its operational and financial landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.